NYSE : NUVB

Nuvation Bio Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 4.77 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.67B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Details

NameNuvation Bio Inc.
SectorHealthcare
IndustryBiotechnology
Employees305
Founded2018
CeoDavid Hung
CountryUnited States
ExchangeNYSE
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS67080N1019
Cusip67080N101
Cik1811063
Sic2834
Stock TypeCommon Stock
Share ClassClass A Shares

Key executives

NameTitle
Dr. David T. Hung M.D.Founder, President, Chief Executive Officer and Chairman
Philippe Pierre SauvageChief Financial Officer and Principal Financial Officer
Dr. Gary Hattersley Ph.D.Chief Scientific Officer
Moses Makunje CPAVice President of Finance and Principal Accounting and Financial Officer
Dr. David C. Hanley Ph.D.Chief Technical Operations Officer
Robert DeVitaVice President of Corporate Development and Investor Relations
Dr. Stephen Dang Ph.D.Chief Legal Officer and Corporate Secretary
Stacy MarkelChief People Officer
Kerry A. WentworthChief Regulatory Officer
Colleen SjogrenChief Commercial Officer

Contact

Address1500 Broadway, Suite 1401, New York, New York 10036, United States
Phone332 208 6102
Websitehttps://www.nuvationbio.com